Elanco Animal Health Incorporated $ELAN Shares Sold by Truist Financial Corp

Truist Financial Corp lessened its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 10.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 173,070 shares of the company's stock after selling 19,864 shares during the quarter. Truist Financial Corp's holdings in Elanco Animal Health were worth $2,471,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ELAN. Allworth Financial LP boosted its stake in Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after purchasing an additional 2,090 shares during the last quarter. NBC Securities Inc. acquired a new stake in Elanco Animal Health during the 1st quarter worth $40,000. Wealthquest Corp acquired a new stake in Elanco Animal Health during the 1st quarter worth $56,000. Covestor Ltd boosted its stake in Elanco Animal Health by 510.9% during the 1st quarter. Covestor Ltd now owns 7,087 shares of the company's stock worth $74,000 after purchasing an additional 5,927 shares during the last quarter. Finally, MRP Capital Investments LLC boosted its stake in Elanco Animal Health by 60.0% during the 1st quarter. MRP Capital Investments LLC now owns 8,000 shares of the company's stock worth $84,000 after purchasing an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Stock Down 1.4%

Shares of NYSE:ELAN opened at $20.06 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The firm has a market capitalization of $9.97 billion, a PE ratio of 23.33, a price-to-earnings-growth ratio of 3.75 and a beta of 1.65. The firm's 50-day moving average is $18.24 and its two-hundred day moving average is $14.34. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $21.76.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ELAN. Zacks Research raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 3rd. UBS Group lifted their price target on Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, August 8th. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target on the stock in a report on Thursday, July 17th. Finally, JPMorgan Chase & Co. upgraded Elanco Animal Health from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $18.00 to $24.00 in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $19.14.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.